THE HEPATOBILIARY DISEASE MARKER SERUM ALANINE AMINOPEPTIDASE PREDOMINANTLY COMPRISES AN ISOFORM OF THE HEMATOLOGICAL MYELOID DIFFERENTIATION ANTIGEN AND LEUKEMIA MARKER CD-13 GP150
THE HEPATOBILIARY DISEASE MARKER SERUM ALANINE AMINOPEPTIDASE PREDOMINANTLY COMPRISES AN ISOFORM OF THE HEMATOLOGICAL MYELOID DIFFERENTIATION ANTIGEN AND LEUKEMIA MARKER CD-13 GP150
复制标题
DOI：
10.1016/0009-8981(93)90008-r
复制
发表时间：
1993-10-29
影响因子：
5
通讯作者：
NANDURKAR, H
中科院分区：
文献类型：
--
作者：
FAVALORO, EJ;BROWNING, T;NANDURKAR, H
在临床化学中，已发现血清丙氨酸氨基肽酶（AAP）水平的测定可用于检测或确认肝内或肝外疾病引起的胆道梗阻。在血液学中，“gp 150”是一种表面表达的蛋白质分子，由属于所谓的“分化簇”（CD-）13的单克隆抗体识别，除了提供潜在的预后价值外，它还被独立地发现是髓性白血病的有用标志物。目前的报告将这两个独立的研究流联系起来，并提供了证据表明肝胆疾病标志物血清AAP主要包含“gp 150”的循环同种型。因此，针对细胞表面髓样“gp 150”产生并与之特异性反应的（CD-13）单克隆抗体能够特异性地且几乎完全地阻断血清（或血浆）AAP活性，否则在其不存在时观察到该活性。这适用于来源于正常个体或患有肝功能障碍（伴或不伴相关胆道梗阻）的患者的血清（或血浆）。在患有阻塞性黄疸的患者的情况下，观察到AAP水平升高，其在与该单克隆抗体预孵育后降至接近正常水平。此外，提供的数据支持流动血液中AAP的不同亚型的观点。最后，提供了白血病病例中AAP活性的初步数据。因此，这些研究应证明用于临床实验室调查参与AAP活动在各种病理过程。
In clinical chemistry, determination of serum alanine aminopeptidase (AAP) levels has been found to be useful for detecting or confirming biliary obstructions from either intra- or extrahepatic disorders. In haematology, 'gp150' is a surface-expressed protein molecule, recognised by monoclonal antibodies belonging to the so-called 'Cluster of Differentiation' (CD-) 13, which has independently been found to be a useful marker of myeloid leukaemia in addition to providing potential prognostic value. The current report links these two independent research streams and provides evidence that the hepatobiliary disease marker, serum AAP, predominantly comprises a circulating isoform of 'gp 1 50'. Thus, a (CD- 1 3) monoclonal antibody raised to, and specifically reactive with, cell surface myeloid 'gp 1 50' is able to specifically and almost completely block serum (or plasma) AAP activity otherwise observed in its absence. This holds true for serum (or plasma) derived both from normal individuals or from patients suffering hepatic dysfunction, with or without associated biliary obstruction. In the case of patients with obstructive jaundice, raised levels of AAP are observed, which fall to near normal levels following preincubation with this monoclonal antibody. In addition, data are presented to support the view of varying isoforms of AAP within flowing blood. Finally, preliminary data is provided on AAP activity in cases of leukaemia. These studies should thus prove of use to clinical laboratories investigating the involvement of AAP activity in various pathological processes.